The treatment of Reparixin, the pharmacological inhibitor of CXCR1 and CXCR2, caused the significant reduction of G-MDSCs numbers, in colon adenocarcinoma HT29 xenograft tumor and colon carcinoma CT26-GM-derived subcutaneous tumor models (108–110). Here, CXCR1 is linked to neoplasm.